ArticleNature cancer2020
Keap1 mutation renders lung adenocarcinomas dependent on Slc33a1.
Erratum issuedOpen access · greenAbstract read
In one paragraph
Article in Nature cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 51 papers.
0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 82 citations in OpenAlex.
- Tumor cell-intrinsic stress states drive sensitivity to CAR T cell therapy in pancreatic cancer.Science advances · 2026Article
- The SLC-ome of membrane transport: from molecular discovery to physiology and clinical applications.Physiological reviews · 2026Review
- Targeting non-small cell lung cancer: Molecular mechanisms and clinical studies (Review).Oncology letters · 2026Review
- SLC33A1-mediated glutathione transport regulates ER redox balance and function.Nature cell biology · 2026Article
- SLC33A1 exports oxidized glutathione to maintain endoplasmic reticulum redox homeostasis.Nature cell biology · 2026Article
- Excess cysteine drives conjugate formation and impairs proliferation of NRF2-activated cancer cells.Nature metabolism · 2026Article
- The lncRNA DAMER selectively guides mNature cell biology · 2026Article
- SLC33A1 exports oxidized glutathione to maintain endoplasmic reticulum redox homeostasis.bioRxiv : the preprint server for biology · 2026Article
- Pharmacological Inhibition of SLC33A1 Promotes Endoplasmic Reticulum Hyperoxidation and Induces Adaptive IRE1/XBP1s Signaling.bioRxiv : the preprint server for biology · 2026Article
- Endoplasmic Reticulum Redoxome: Protein Folding and Beyond.Biochemistry · 2026Review
- Targeting NRF2 addiction in cancer: synthetic lethal strategies beyond direct inhibition.Frontiers in cell and developmental biology · 2026Review
- Loss of UXS1 Selectively Depletes Pyrimidines and Induces Replication Stress in KEAP1-Mutant Lung Cancer.Cancer research · 2025Article
- Tumor nutrient stress gives rise to a drug tolerant cell state in pancreatic cancer.bioRxiv : the preprint server for biology · 2025Article
- Advances in molecular pathology and therapy of non-small cell lung cancer.Signal transduction and targeted therapy · 2025Review
- Four-year outcomes with perioperative toripalimab plus chemotherapy in resectable stage III non-small cell lung cancer (NeoTAP01 study).Journal of thoracic disease · 2025Article
- Construction of a lung adenocarcinoma prognostic model based on KEAP1/NRF2/HO‑1 mutation‑mediated upregulated genes and bioinformatic analysis.Oncology letters · 2025Article
- Article
- Oncogenic TFE3 fusions drive OXPHOS and confer metabolic vulnerabilities in translocation renal cell carcinoma.Nature metabolism · 2025Article
- KEAP1-NRF2 Interaction in Cancer: Competitive Interactors and Their Role in Carcinogenesis.Cancers · 2025Review
- Kelch-like ECH-associated Protein 1/Nuclear Factor Erythroid 2-related Factor 2 Pathway and Its Interplay with Oncogenes in Lung Tumorigenesis.Journal of cancer prevention · 2024Review
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
19 authors at 9 institutions in 1 country.
Rodrigo Romero *Koch Institute for Integrative Cancer Research, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-9388-8306
Francisco J Sánchez-Rivera *Koch Institute for Integrative Cancer Research, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-8466-8563
Peter M K WestcottKoch Institute for Integrative Cancer Research, Cambridge, MA, USA.
Kim L MercerKoch Institute for Integrative Cancer Research, Cambridge, MA, USA.
Arjun BhutkarKoch Institute for Integrative Cancer Research, Cambridge, MA, USA.
Alexander MuirKoch Institute for Integrative Cancer Research, Cambridge, MA, USA.
Tania J González RoblesKoch Institute for Integrative Cancer Research, Cambridge, MA, USA.
Swanny Lamboy RodríguezMassachusetts Institute of Technology Department of Biology, Cambridge, MA, USA.
Laura Z LiaoMassachusetts Institute of Technology Department of Biology, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-1277-0956
Sheng Rong NgKoch Institute for Integrative Cancer Research, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-1655-2443
Leanne LiKoch Institute for Integrative Cancer Research, Cambridge, MA, USA.
Caterina I ColónKoch Institute for Integrative Cancer Research, Cambridge, MA, USA.
Santiago NaranjoKoch Institute for Integrative Cancer Research, Cambridge, MA, USA.
Mary Clare BeytaghMassachusetts Institute of Technology Department of Biology, Cambridge, MA, USA.
Caroline A LewisWhitehead Institute, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-1787-5084
Peggy P HsuKoch Institute for Integrative Cancer Research, Cambridge, MA, USA.
Roderick T BronsonTufts University, Boston, MA, USA.
Matthew G Vander HeidenKoch Institute for Integrative Cancer Research, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-6702-4192
Tyler JacksKoch Institute for Integrative Cancer Research, Cambridge, MA, USA. tjacks@mit.edu.ORCID http://orcid.org/0000-0001-5785-8911
Allen Institute · USMassachusetts Institute of Technology · USHoward Hughes Medical Institute · USDana-Farber Cancer Institute · USMassachusetts General Hospital · USMemorial Sloan Kettering Cancer Center · USTufts University · USUniversity of Chicago · USWhitehead Institute for Biomedical Research · US
Funding
VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Jacqueline A. Lees · 1985 to 2026
$93.9MPRE-DOCTORAL TRAINING IN THE BIOLOGICAL SCIENCEST32GM007287 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BELL, STEPHEN P., KEATING, AMY E · 1985 to 2019
$40.8MTraining Program in Cancer Biology and TherapeuticsT32CA071345 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Daniel A. Haber, Lecia V. Sequist · 1997 to 2026
$10.6MDevelopment of a novel platform for the identification of synthetic lethal genes in a Kras and Keap1-mutant mouse model of lung adenocarcinoma.F31CA224796 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI ROMERO, RODRIGO · 2017 to 2019
$70kHoward Hughes Medical InstituteNCI NIH HHS F31 CA224796NCI NIH HHS P30 CA014051NCI NIH HHS T32 CA071345NIGMS NIH HHS T32 GM007287
Abstract
Approximately 20-30% of human lung adenocarcinomas (LUAD) harbor loss-of-function (LOF) mutations in Kelch-like ECH Associated-Protein 1 (
Indexed as
Adenocarcinoma of LungKelch-Like ECH-Associated Protein 1Lung NeoplasmsMembrane Transport ProteinsAnimalsHumansMiceMutationNF-E2-Related Factor 2KEAP1 protein, humanKeap1 protein, mouseKelch-Like ECH-Associated Protein 1Membrane Transport ProteinsNF-E2-Related Factor 2SLC33A1 protein, humanSlc33a1 protein, mouse
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.